Phio Pharmaceuticals Corp. (PHIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US71880W5013
Phio Pharmaceuticals Corp. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.22 m USD |
| EBIT | -8.70 m USD |
| Net income | -8.70 m USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
More stocks
- Lexaria Bioscience Corp. (LEXX)
- BT Brands, Inc. (BTBD)
- Caring Brands, Inc. (CABR)
- AVALON HOLDINGS CORP (AWX)
- Foxx Development Holdings Inc. (FOXX)
- TEN Holdings, Inc. (XHLD)
- AZIO AI HOLDINGS, INC. (AZIO)
- Offerpad Solutions Inc. (OPAD)
- BION ENVIRONMENTAL TECHNOLOGIES INC (BNET)
- DIXIE GROUP INC (DXYN)
- Concrete Leveling Systems Inc (CLEV)
- Trio Petroleum Corp (TPET)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.